A research group based in Pakistan has had 10 of their papers retracted from Wiley’s Food Science & Nutrition based on flaws in the peer review process.
According to the notices, which were identical for each article, “the editorial office found unambiguous evidence that the manuscript was accepted solely based on compromised and insufficient reviewer reports.”
The following articles have been retracted:
Continue reading Food science journal retracts 10 papers for compromised peer review
A journal has retracted an entire special issue over concerns the guest-edited papers underwent a “compromised” peer review process.
In a supplement to Volume 337 Issue 1 of Annals of Operations Research, 23 papers were retracted with the same statement:
The Editor-in-Chief and the publisher have retracted this article. The article was submitted to be part of a guest-edited issue. An investigation by the publisher found a number of articles, including this one, with a number of concerns, including but not limited to compromised editorial handling and peer review process, inappropriate or irrelevant references or not being in scope of the journal or guest-edited issue. Based on the investigation’s findings the Editor-in-Chief therefore no longer has confidence in the results and conclusions of this article.
The articles in the guest-edited issue, Prescriptive Analytics Using Machine Learning and Mathematical Programming for Sustainable Operations Research, were published between June 2022 and October 2023.
Continue reading ‘We authors paid a heavy price’: Journal retracts all 23 articles in special issue
Would you consider a donation to support Weekend Reads, and our daily work?
The week at Retraction Watch featured:
Our list of retracted or withdrawn COVID-19 papers is up past 400. There are more than 49,000 retractions in The Retraction Watch Database — which is now part of Crossref. The Retraction Watch Hijacked Journal Checker now contains more than 250 titles. And have you seen our leaderboard of authors with the most retractions lately — or our list of top 10 most highly cited retracted papers? What about The Retraction Watch Mass Resignations List — or our list of nearly 100 papers with evidence they were written by ChatGPT?
Here’s what was happening elsewhere (some of these items may be paywalled, metered access, or require free registration to read):
Continue reading Weekend reads: Huge cash bonuses for publishing in Nature; Alzheimer’s researcher charged with fraud; fines for buying authorship
A panel of scholars in Finland has downgraded 60 journals in their quality rating system, following months of review and feedback from researchers.
The Finnish Publication Forum (JUFO) classifies and rates journals and other scholarly publications to “support the quality assessment of academic research,” according to its website. JUFO considers the level of transparency, the number of experts on a publication’s editorial board, and the standard of peer review to make its assessment, which academics can use to determine the credibility of a given title or its publisher.
JUFO’s classification ranges from 3, for “supreme-level” publications, to 1, which still counts as legitimate publication. Level 0 means the journal is excluded from the ranking, which may dissuade researchers from publishing with them, James Heathers, a scientific sleuth said. Finland’s university funding model relies on JUFO as a publication quality metric.
Continue reading Finland group downgrades 60 journals
The corresponding author of a paper flagged on PubPeer for an apparently duplicated image will be asking the journal to publish a correction, Retraction Watch has learned.
The paper, “The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs,” appeared in Oncotarget in 2016. Its authors include Marcel Dinger, now a dean at the University of Sydney, who has said he’s working to correct review papers that cited papermill articles, and sleuth Jennifer A. Byrne, also of the University of Sydney.
Earlier this month, an anonymous user on PubPeer pointed out areas of images in figure 6B that were “much more similar than expected.”
Continue reading Authors – including a dean and a sleuth – correcting paper with duplicated image
Clarivate, the company that calculates Journal Impact Factors based on citations to articles, didn’t publish the metric for 17 journals this year due to suspected citation manipulation. That’s a substantial increase from last year, when only four were excluded.
The increase is, in part, case of rising tides lifting (sinking?) all boats: In its 2024 Journal Citation Reports, Clarivate included an additional 7,200 journals from the Emerging Sources Citation Index (ESCI) and the the Arts and Humanities Citation Index (AHCI), a spokesperson for the company said, resulting in a larger number of impact factor suppressions than in past years.
Clarivate suppressed nearly twice as many journals in 2020, when it penalized 33 for self-citation. The company suppressed 10 in 2021, and three the following year.
Continue reading Seventeen journals lose impact factors for suspected citation manipulation
A 2020 paper that claimed to find a link between microbial genomes in tissue and cancer has been retracted following an analysis that called the results into question.
The paper, “Microbiome analyses of blood and tissues suggest cancer diagnostic approach,” was published in March 2020 and has been cited 610 times, according to Clarivate’s Web of Science. It was retracted June 26. The study was also key to the formation of biotech start-up Micronoma, which did not immediately respond to our request for comment.
Rob Knight, corresponding author and researcher at the University of California San Diego, also did not immediately respond to our request for comment.
Continue reading ‘All authors agree’ to retraction of Nature article linking microbial DNA to cancer
Cureus has retracted a 2024 case study after learning it had published a piece about the identical patient, by authors from the same institution, just months earlier.
The paper, “Lipoma Growing on the Back for 26 Years: A Bizarre Case Report,” was published March 26 and retracted June 17. Three of the four authors are affiliated with Datta Meghe Institute of Higher Education and Research, in Wardha, India. The corresponding author, Samiksha V. Gupta, was a medical student at the institution but has since received his degree.
The notice states:
Continue reading Journal retracts redundant case study of same patient from different authors
I was once required to testify in a court case. My lawyer gave me a few pieces of advice, but he repeated one several times, which may be why I remember it. “Never say never,” he said. Or, conversely, never say always. Declarations of absolutes present opposing attorneys too wide an opening. They need to identify only a single example to contradict. In trial courts, one cannot get away with making reckless absolutist claims unchallenged.
In academic scholarship, however, it happens all the time.
Meet the dismissive literature review, in which an author at the beginning of a journal article declares the published research literature on the topic either nonexistent or so poor in quality that all of it is … dismissible. Typically, no evidence supports the claim. You’ve seen the claims yourself (e.g., “little previous research has, …” “few studies have looked at …,” “there is no research on …,” etc.). With one type of dismissive review — a firstness claim — authors boldly declare themselves to be the first in the history of the world to study a particular topic (as in, “this is the first study of …”).
Continue reading What a database of more than a thousand dismissive literature reviews can tell us
A paper that purported to find vitamin D could reduce the severity of COVID-19 symptoms has been retracted from PLOS ONE, four years after the journal issued an expression of concern about the research.
The article, “Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection,” appeared online September 25, 2020. Michael F. Holick, a professor of medicine at Boston University and a proponent of the use of vitamin D, was the last author among a group of other researchers from the Tehran University of Medical Sciences in Iran.
Soon after publication, the paper gained traction on platforms like Twitter (now X) as evidence vitamin D could treat COVID-19 symptoms.
Amidst this discussion, Nick Brown, a science integrity researcher at Linnaeus University in Växjö, Sweden, and Gideon Meyerowitz-Katz, a research fellow at the University of Wollongong, Australia, pointed out potential flaws with the work, including the small sample size of the study and a lack of patient information such as how the patients died.
Continue reading Paper recommending vitamin D for COVID-19 retracted four years after expression of concern